<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02212756</url>
  </required_header>
  <id_info>
    <org_study_id>DW1029M-I-4</org_study_id>
    <nct_id>NCT02212756</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Profiles of Metformin With DW1029M</brief_title>
  <acronym>PMD</acronym>
  <official_title>A Randomized, Open-label, Multiple-dose, Crossover Phase I Clinical Study to Evaluate DW1029M Influence the Pharmacokinetic Profiles of Metformin After Oral Administration in Healthy Male Volunteer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong Wha Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong Wha Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I clinical study to evaluate DW1029M influence the pharmacokinetic profiles of&#xD;
      Metformin after oral administration in healthy male volunteer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, open-label, multiple-dose, crossover phase I clinical study to evaluate DW1029M&#xD;
      influence the pharmacokinetic profiles of Metformin after oral administration in healthy male&#xD;
      volunteer&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax and AUC</measure>
    <time_frame>1d/15d, 5d/19d, 6d/20d : Predose(0,morning), 7d/21d: Predose(0), 1, 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12 h</time_frame>
    <description>Maximum of Concentration(Cmax), Area Under Plasma Concentration-Time Curve(AUC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile of Plasma</measure>
    <time_frame>1d/15d, 5d/19d, 6d/20d: Predose(0, Morning), 7d/21d: Predose(0), 1, 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12 h</time_frame>
    <description>Maximum drug concentration time(Tmax), Half-time(t1/2), Apparent renal clearance(CL/F), Apparent volume of distribution(Vd/F), Fluctuation[(Css,max-Css,min)/Css,av], Swing[(Css,max-Css,min)/Css,min]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>B Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st oral administration of Metformin 1000mg and 2nd oral administration of Metformin 1000mg and DW1029M 1200mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st oral administration of DW1029M 1200mg and Metformin 1000mg and 2nd oral administration of Metformin 1000mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DW1029M 1200mg and Metformin 1000mg</intervention_name>
    <description>Metformin 500mg 1 Tablet and DW1029M 300mg 2 Tablets b.i.d. for 7days</description>
    <arm_group_label>A Group</arm_group_label>
    <arm_group_label>B Group</arm_group_label>
    <other_name>Concomitant of DW1029M 1200mg and Metformin 1000mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin 1000mg</intervention_name>
    <description>Metformin 500mg b.i.d. for 7 days</description>
    <arm_group_label>A Group</arm_group_label>
    <arm_group_label>B Group</arm_group_label>
    <other_name>Diabex tab. 500mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  a healthy adult within the range of 19 to 55 years old at the time of screening&#xD;
&#xD;
          -  Body Mass Index(BMI)=17.5~30.5kg/m2, one with weight of more than 55kg (BMI= kg/(m)2)&#xD;
&#xD;
          -  Congenital or chronic diseases within the last three years, there is no medical&#xD;
             examination results of popular characters with no psychotic symptoms or findings&#xD;
&#xD;
          -  Depending on the nature of the drug your doctor check conducted hematology, blood&#xD;
             chemistry, urinalysis and laboratory tests, including an electrocardiogram(EKG)&#xD;
             performed during screening tests such as a suitable test subjects who judged&#xD;
&#xD;
          -  The purpose of the test participants prior to testing, information, and to hear about&#xD;
             the free will fully explain to participate in this study, according to the&#xD;
             Institutional Review Board(IRB)-approved consent form signed by the parties in writing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  one with clinically significant blood, kidneys, endocrine, respiratory,&#xD;
             gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurological or&#xD;
             allergic disease (but ,except for untreated seasonal allergies of asymptomatic at the&#xD;
             time of administration) with medical history or evidence&#xD;
&#xD;
          -  one with gastrointestinal disease(Such as esophageal stricture or achalasia of the&#xD;
             esophagus disease, Crohn disease) to affect drug absorption or surgery(but, excluding&#xD;
             simple appendectomy or hernia surgery) with medical history&#xD;
&#xD;
          -  Alanine Aminotransferase(ALT) or Aspartate Aminotransferase(AST) &gt; 2 times the upper&#xD;
             limit of the normal range&#xD;
&#xD;
          -  Within 6 months, 210 g / week of alcohol in excess of a history of regular characters&#xD;
             (beer (5%) 1 cup (250 mL) = 10 g, soju(20%) 1 cup (50 mL) = 8 g, Wine (12%) 1 cup (125&#xD;
             mL) = 12 g)&#xD;
&#xD;
          -  Take part in other clinical trials within two months&#xD;
&#xD;
          -  Systolic Blood Pressure(SBP) ≥ 140 mmHg or Diastolic Blood Pressure (DBP) ≥ 90 mmHg&#xD;
&#xD;
          -  The great history of alcohol or drug abuse within 1 year&#xD;
&#xD;
          -  Taking medication of drug-metabolizing enzymes that are known to significantly induce&#xD;
             or inhibit within 30 days&#xD;
&#xD;
          -  More than 20 cigarettes a day smoker&#xD;
&#xD;
          -  Taking medication of a prescription drug or nonprescription within 10 days,&#xD;
&#xD;
          -  Within two months the whole blood donation have, within one month of the apheresis&#xD;
             donation have&#xD;
&#xD;
          -  Participate in clinical trials to test drug administration and may be at increased&#xD;
             risk due to interpretation of test results, or may interfere with severe supply /&#xD;
             chronic medical or mental condition or abnormal laboratory test values in character&#xD;
&#xD;
          -  Kidney disease or renal insufficiency (serum creatinine &gt; 1.5mg/dL(man),&#xD;
             1.4mg/dL(women), or abnormal creatinine clearance) in patients&#xD;
&#xD;
          -  Patients with congestive heart failure that requires medication&#xD;
&#xD;
          -  Intravenous urography, intravenous cholangiography, angiography, computer&#xD;
             tomography(CT) contrast agent for patients&#xD;
&#xD;
          -  Investigational product component or biguanide drug in patients with a history of&#xD;
             hypersensitivity&#xD;
&#xD;
          -  Patients with acute or chronic metabolic acidosis and a history of ketoacidosis&#xD;
&#xD;
          -  Severe systemic infection or severe trauma disorders&#xD;
&#xD;
          -  Nutritional status, hunger, debilitating condition, pituitary or adrenal dysfunction&#xD;
             dysfunction&#xD;
&#xD;
          -  Pulmonary infarction, severe lung function disorders and hypoxemia, excessive alcohol&#xD;
             intake, party, dehydration, diarrhea, vomiting and other gastrointestinal disorders&#xD;
&#xD;
          -  Described lifestyle in this protocol can comply with or can not&#xD;
&#xD;
          -  one with other investigator judge to unsuitable&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mingul Kim, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabuk-do</state>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>August 5, 2014</study_first_submitted>
  <study_first_submitted_qc>August 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2014</study_first_posted>
  <last_update_submitted>June 25, 2015</last_update_submitted>
  <last_update_submitted_qc>June 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

